Evofem Biosciences shares rose 38 percent after the company’s birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.

Roche gained 510(k) clearance from the U.S. Food and Drug Administration for cobas CT/NG for use on the cobas 6800/8800 Systems for the detection of chlamydia and gonorrhea in both symptomatic and asymptomatic patients.